The latest update is out from Compass Therapeutics ( (CMPX) ).
On April 1, 2025, Compass Therapeutics announced that its investigational bispecific antibody, tovecimig, met the primary endpoint in a Phase 2/3 trial for advanced biliary tract cancer (BTC), showing a statistically significant improvement in overall response rate when combined with paclitaxel compared to paclitaxel alone. The trial’s top-line data revealed a 17.1% overall response rate for the combination therapy, highlighting its potential as a much-needed treatment option for BTC patients with limited alternatives, and the company plans to report further data on secondary endpoints in the fourth quarter of 2025.
More about Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company based in Boston, Massachusetts. It develops proprietary antibody-based therapeutics targeting angiogenesis, the immune system, and tumor growth, with a pipeline designed to modulate microvasculature, induce immune responses, and alleviate tumor immunosuppression.
YTD Price Performance: 35.71%
Average Trading Volume: 1,583,123
Technical Sentiment Signal: Hold
Current Market Cap: $275.2M
For a thorough assessment of CMPX stock, go to TipRanks’ Stock Analysis page.